Sunshine Biopharma announces Nora Pharma launch of two new generic drugs

Sunshine Biopharma announced that its wholly owned Canadian subsidiary, Nora Pharma Inc., has launched two new generic prescription drugs. The first product is Varenicline, a generic version of Champix. Varenicline is used as a smoking cessation product and is available in formats of 0.5 mg and 1 mg tablets, as well as a starter kit. The second is Betahistine, a generic version of Serc, to treat patients with vertigo. Betahistine is available in formats of 8 mg, 16 mg and 24 mg scored tablets. “Propelled by Sunshine Biopharma’s strategic support, Nora Pharma plans to continue its rapid top-line and bottom-line growth,” said Malek Chamoun, president of Nora Pharma.